Form 4: Medifast Director Jeffrey Brown Reports Stock Transactions
SEC Form 4 Filing
Director Jeffrey Brown reports acquisition of Medifast stock through restricted stock units and election to receive shares in lieu of cash compensation.
Summary
- Jeffrey Brown, a director at Medifast, Inc., filed a Form 4 detailing changes in beneficial ownership.
- On June 20, 2024, Brown acquired 6,596 restricted stock units under the Medifast, Inc. Director's Deferred Compensation Plan, which will vest on June 20, 2025.
- Brown also acquired 5,581 shares of common stock in lieu of cash compensation for annual service as a non-employee director, at a price of $22.66 per share based on the 20-day moving average.
- Following these transactions, Brown directly owns 17,960.647 shares and indirectly owns 4,232.967 shares through the Jeffrey Brown Living Trust.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it reflects standard director compensation practices and alignment of interests with shareholders.
Positives
- The director's acquisition of shares reflects confidence in the company's future.
- The election to receive shares instead of cash compensation aligns the director's interests with those of shareholders.
Industry Context
Directors receiving stock options and deferred compensation is a common practice to align management interests with shareholders. The amount of stock received is not significant enough to move the market.
Comparison to Industry Standards
- Director compensation packages vary widely across the industry, but equity-based compensation is a common component.
- Comparing Medifast's director compensation to similar companies like Herbalife or Nu Skin could provide further context, but the details of those packages are not available in this document.
- The vesting schedule of the restricted stock units is typical, aligning with standard practices for long-term incentives.
Stakeholder Impact
- The transactions signal to shareholders that the director is invested in the company's long-term success.
- Employees may view the director's stock acquisition as a positive sign of company stability.
Key Dates
| Date | Description |
|---|---|
| 06/18/2024 | Date used to calculate the 20-day moving average stock price of $22.66 per share. |
| 06/20/2024 | Date of the stock transactions: acquisition of restricted stock units and shares in lieu of cash compensation. |
| 06/20/2025 | Vesting date for the 6,596 restricted stock units granted under the Medifast, Inc. Director's Deferred Compensation Plan. |
| 06/24/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.